Sulfonylurea Response in Patients With Diabetes Due to Kir6.2 Mutations

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate whether patients with diabetes due to Kir6.2 mutations can be treated with sulfonylurea medication rather than insulin, and if this is the case to investigate the mechanism for sulfonylurea response.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Royal Devon and Exeter NHS Foundation Trust
• Collaborators: Haukeland University Hospital; Hôpital Necker-Enfants Malades; Wellcome Trust

Criteria

Inclusion Criteria:

• Diabetes due to KCNJ11 (Kir6.2) mutation

Exclusion Criteria:

• None